Will Eli Lilly announce that Jaypirca (pirtobrutinib) is commercially available in the U.S. for previously untreated CLL/SLL on or before 2026-11-15?
Avaldatud 2026-10-03 — 43 päeva enne tähtaega, väidetud enne tulemuse selgumist.
Eli Lilly is a pharmaceutical company that develops and markets prescription medicines. Jaypirca (pirtobrutinib) is one of its products indicated for certain hematologic malignancies, including chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Commercial availability for a new patient population in the United States depends on regulatory authorization and subsequent company announcements.
Väide
Eli Lilly will announce that Jaypirca (pirtobrutinib) is commercially available in the U.S. for previously untreated CLL/SLL on or before 2026-11-15.
Põhjendusahel
- The FDA approved the expanded Jaypirca indication for previously untreated CLL/SLL on October 3, 2026
- Eli Lilly typically moves newly approved oncology indications to commercial availability within weeks
- The company issues a launch availability announcement to support first-line CLL/SLL adoption
- The availability announcement occurs by November 15, 2026
Tõendid seni
1 kinnitavat · 0 ümberlükkavat signaali · 4 kinnitust · 0 murtud eeldust. Tõendid ise on osa täisdossiest.
Tõenäosuse ajalugu
Uuendatud 5 korda alates lisamisest (viimati 2026-10-09) — 70% alguses → 81% täna.
Mida jälgida
- eeltingimus Eli Lilly submits a New Drug Application (NDA) to the FDA for the expanded indication of Jaypirca in previously untreated CLL/SLL
- juhtnäitaja Eli Lilly lists Jaypirca (pirtobrutinib) with the new indication on its official product page or corporate website
- juhtnäitaja Eli Lilly issues a public press release announcing the commercial launch of Jaypirca for previously untreated CLL/SLL
Selle ennustuse taga olev täisdossier — tõendite jälg, riskianalüüs, rahastamisstsenaariumid — on saadaval soovi korral: [email protected].
Tõenäosused on kalibreeritud süsteemi enda lahendatud ajaloo põhjal; pärast tähtaega tulemus lahendatakse ja auditeeritakse — kaasa arvatud need, milles me eksisime. Miski sellel lehel ei ole investeerimisnõuanne.